Recent advances in α-1-antitrypsin deficiency-related lung disease

Expert Review of Respiratory Medicine

Volumn 7, Issue 3, 2013, Pages 213-230

  Brebner, Judith A ^a   Stockley, Robert A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

augmentation; biomarker; chronic obstructive pulmonary disease; emphysema; gene therapy; polymerization; 1 antitrypsin

Indexed keywords

ALFALASTIN; ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; ARALAST NP; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CATHEPSIN B; CHEMOKINE; DESMOSINE; ELASTIN; GELATINASE A; GELATINASE B; GLASSIA; INFLUENZA VACCINE; LEUKOTRIENE B4; LIPOSOME; PALOVAROTENE; PARVOVIRUS VECTOR; PLACEBO; PROLASTIN C; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; STEROID; TRYPSAN; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALPHA HELIX; BETA SHEET; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SCREENING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG DISEASE; LUNG EMPHYSEMA; LUNG RESECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT MONITORING; PHENOTYPE; PLURIPOTENT STEM CELL; PNEUMONIA; POLYMERIZATION; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL AIRWAY DISEASE; SMOKING CESSATION; STEM CELL GENE THERAPY; VACCINATION; VIRAL GENE THERAPY;

EID: 84878678178     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.13.20     Document Type: Review

References (156)

1. Laurell CB, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand. J. Clin. Lab. Invest. 15, 132-140 (1963).
2. Brantly M, Nukiwa T, Crystal RG. Molecular basis of α-1-antitrypsin deficiency. Am. J. Med. 84(6A), 13-31 (1988).
3. Fagerhol MK, Laurell CB. The polymorphism of 'prealbumins' and α-1-antitrypsin in human sera. Clin. Chim. Acta 16(2), 199-203 (1967).
4. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in α 1-antitrypsin deficiency. N. Engl. J. Med. 314(12), 736-739 (1986).
5. Smith KC, Pittelkow MR, Su WP. Panniculitis associated with severe α 1-antitrypsin deficiency. Treatment and review of the literature. Arch. Dermatol. 123(12), 1655-1661 (1987).
6. Shin MS, Ho KJ. Bronchiectasis in patients with α 1-antitrypsin deficiency. A rare occurrence? Chest 104(5), 1384-1386 (1993).
7. Mahr AD, Edberg JC, Stone JH, et al. α1-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum. 62(12), 3760-3767 (2010).
8. Guidelines for the approach to the patient with severe hereditary α-1-antitrypsin deficiency. American Thoracic Society. Am. Rev. Respir. Dis. 140, 1494-1497 (1989).
9. Hutchison DC. α 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir. Med. 92(3), 367-377 (1998).
10. Blanco I, Fernández E, Bustillo EF. α-1-antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. Clin. Genet. 60(1), 31-41 (2001).
11. de Serres FJ, Blanco I. Prevalence of a1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther. Adv. Respir. Dis. 6(5), 277-295 (2012).
12. Miravitlles M, Herr C, Ferrarotti I, et al. Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres. Eur. Respir. J. 35(5), 960-968 (2010).
13. Rodriguez-Frias F, Miravitlles M, Vidal R, Camos S, Jardi R. Rare α-1-antitrypsin variants: are they really so rare? Ther. Adv. Respir. Dis. 6(2), 79-85 (2012).
14. Stockley RA, Luisetti M, Miravitlles M, Piitulainen E, Fernandez P; Alpha One International Registry (AIR) group. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur. Respir. J. 29(3), 582-586 (2007).
15. Bornhorst JA, Greene CM, Ashwood ER, Grenache DG. α 1-antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest 143(4), 1000-1008 (2013).
16. Curiel DT, Holmes MD, Okayama H, et al. Molecular basis of the liver and lung disease associated with the α 1-antitrypsin deficiency allele Mmalton. J. Biol. Chem. 264(23), 13938-13945 (1989).
17. Ferrarotti I, Baccheschi J, Zorzetto M, et al. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for α1-antitrypsin deficiency. J. Med. Genet. 42(3), 282-287 (2005).
18. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with α-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 168, 818-900 (2003).
19. Campos M, Shmuels D, Walsh J. Detection of α-1 antitrypsin deficiency in the US. Am. J. Med. 125(7), 623-624 (2012).
20. de Serres FJ, Blanco I, Fernández-Bustillo E. Estimating the risk for α-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening. COPD 3(3), 133-139 (2006).
21. Davies MJ, Lomas DA. The molecular aetiology of the serpinopathies. Int. J. Biochem. Cell Biol. 40(6-7), 1273-1286 (2008).
22. Whisstock J, Skinner R, Lesk AM. An atlas of serpin conformations. Trends Biochem. Sci. 23(2), 63-67 (1998).
23. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407(6806), 923-926 (2000).
24. Whisstock JC, Bottomley SP. Molecular gymnastics: serpin structure, folding and misfolding. Curr. Opin. Struct. Biol. 16(6), 761-768 (2006).
25. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z α 1-antitrypsin accumulation in the liver. Nature 357(6379), 605-607 (1992).
26. Yamasaki M, Li W, Johnson DJ, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455(7217), 1255-1258 (2008).
27. Miranda E, Pérez J, Ekeowa UI, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with α1-antitrypsin deficiency. Hepatology 52(3), 1078-1088 (2010).
28. Ekeowa UI, Freeke J, Miranda E, et al. Defining the mechanism of polymerization in the serpinopathies. Proc. Natl Acad. Sci. USA 107(40), 17146-17151 (2010).
29. Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA. Molecular basis of a1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep. 12(10), 1011-1017 (2011).
30. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78, 147-176 (2009).
31. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. Am. Rev. Respir. Dis. 116(3), 469-475 (1977).
32. Turino GM. The origins of a concept: the protease-antiprotease imbalance hypothesis. Chest 122(3), 1058-1060 (2002).
33. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal Jr. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J. Clin. Invest. 82(6), 1963-1973 (1988).
34. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with α-1-antitrypsin deficiency and COPD. Eur. Respir. J. 41(5), 1042-1050 (2013).
35. Churg A, Zhou S, Wright JL. Series 'matrix metalloproteinases in lung health and disease': matrix metalloproteinases in COPD. Eur. Respir. J. 39(1), 197-209 (2012).
36. Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am. Rev. Respir. Dis. 145(3), 661-668 (1992).
37. Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J. Immunol. 178(9), 5871-5878 (2007).
38. Sullivan A, Stockley RA. Proteinases in COPD. In: Recent Advances in the Pathophysiology of COPD. Hansel TT, Barnes PJ (Eds). Birkhauser Verlag, Basel, Switzerland (2004).
39. Morrison HM, Kramps JA, Burnett D, Stockley RA. Lung lavage fluid from patients with α 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin. Sci. 72(3), 373-381 (1987).
40. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and α1-antitrypsin deficiency. Eur. Respir. J. 15(5), 886-890 (2000).
41. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of α(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax 57(8), 709-714 (2002).
42. Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in α 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J. Clin. Invest. 88(3), 891-897 (1991).
43. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 165(11), 1494-1498 (2002).
44. Houghton AM, Quintero PA, Perkins DL, et al. Elastin fragments drive disease progression in a murine model of emphysema. J. Clin. Invest. 116(3), 753-759 (2006).
45. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z α1-antitrypsin deficiencyrelated emphysema. Am. J. Respir. Cell Mol. Biol. 18(5), 670-674 (1998).
46. Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of α(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am. J. Respir. Cell Mol. Biol. 26(6), 723-730 (2002).
47. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z α1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am. J. Pathol. 166(2), 377-386 (2005).
48. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in α1-antitrypsin deficiency: molecular and cellular insights. Eur. Respir. J. 34(2), 475-488 (2009).
49. Mulgrew AT, Taggart CC, Lawless MW, et al. Z α1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 125(5), 1952-1957 (2004).
50. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of α(1)-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 160(5 Pt 1), 1468-1472 (1999).
51. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency. Eur. Respir. J. 33(6), 1345-1353 (2009).
52. Greene CM, Hassan T, Molloy K, McElvaney NG. The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and a-1 anti-trypsin deficiency. Expert Rev. Respir. Med. 5(3), 395-411 (2011).
53. Greene CM, McElvaney NG. Z a-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J. Gastrointest. Pharmacol. Ther. 1(5), 94-101 (2010).
54. Gishen P, Saunders AJ, Tobin MJ, Hutchison DC. α 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin. Radiol. 33(4), 371-377 (1982).
55. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in α1-antitrypsin deficiency influences lung function impairment. Am. J. Respir. Crit. Care Med. 170(11), 1172-1178 (2004).
56. Gurney JW, Jones KK, Robbins RA, et al. Regional distribution of emphysema: correlation of high-resolution CT with pulmonary function tests in unselected smokers. Radiology 183(2), 457-463 (1992).
57. King MA, Stone JA, Diaz PT, Mueller CF, Becker WJ, Gadek JE. α 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 199(1), 137-141 (1996).
58. Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 176(12), 1215-1221 (2007).
59. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of α(1)-antitrypsin alleles in patients with bronchiectasis. Chest 117(2), 415-419 (2000).
60. Chan ED, Iseman MD. Significance of bronchiectasis in patients with α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 178(2), 208; author reply 208-208; author reply 209 (2008).
61. Eden E, Hammel J, Rouhani FN, et al. Asthma features in severe α1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest 123(3), 765-771 (2003).
62. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin; the Alpha-1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med. 158, 49-59 (1998).
63. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in α1-antitrypsin deficiency. Eur. Respir. J. 33(6), 1338-1344 (2009).
64. Eden E. Asthma and COPD in α-1 antitrypsin deficiency. Evidence for the Dutch hypothesis. COPD 7(5), 366-374 (2010).
65. Holme J, Stockley RA. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from α1-antitrypsin deficiency. Chest 132(3), 909-915 (2007).
66. Piras B, Ferrarotti I, Lara B, et al. Clinical phenotypes of Italian and Spanish patients with α-1-antitrypsin deficiency. Eur. Respir. J. doi:10.1183/09031936.00104712 (2012) (Epub ahead of print).
67. Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe α-1-antitrypsin deficiency. Thorax 62(9), 806-813 (2007).
68. DeMeo DL, Silverman EK. α1-antitrypsin deficiency. 2: genetic aspects of α(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 59(3), 259-264 (2004).
69. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in α 1-antitrypsin deficiency. Quantitative phenotypes. Am. Rev. Respir. Dis. 142(5), 1015-1021 (1990).
70. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotypic differences in α 1 antitrypsin-deficient sibling pairs may relate to genetic variation. COPD 5(6), 353-359 (2008).
71. DeMeo DL, Campbell EJ, Brantly ML, et al. Heritability of lung function in severe α-1 antitrypsin deficiency. Hum. Hered. 67(1), 38-45 (2009).
72. Castaldi PJ, Demeo DL, Hersh CP, et al.; AATGM Investigators; ICGN Investigators. Impact of non-linear smoking effects on the identification of gene-bysmoking interactions in COPD genetics studies. Thorax 66(10), 903-909 (2011).
73. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in α1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 59(10), 843-849 (2004).
74. Sørheim IC, Bakke P, Gulsvik A, et al. a1-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 138(5), 1125-1132 (2010).
75. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type α 1-antitrypsin is less competent than M1-type α 1-antitrypsin as an inhibitor of neutrophil elastase. J. Clin. Invest. 80(5), 1366-1374 (1987).
76. Novoradovsky A, Brantly ML, Waclawiw MA, et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in α1-antitrypsin deficiency. Am. J. Respir. Cell Mol. Biol. 20(3), 441-447 (1999).
77. Rodriguez F, de la Roza C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase P1 and lung function in patients with α1-antitrypsin deficiency and COPD. Chest 127(5), 1537-1543 (2005).
78. Demeo DL, Campbell EJ, Barker AF, et al. IL10 polymorphisms are associated with airflow obstruction in severe α1-antitrypsin deficiency. Am. J. Respir. Cell Mol. Biol. 38(1), 114-120 (2008).
79. Wood AM, Simmonds MJ, Bayley DL, Newby PR, Gough SC, Stockley RA. The TNFα gene relates to clinical phenotype in α-1-antitrypsin deficiency. Respir. Res. 9, 52 (2008).
80. Kim WJ, Wood AM, Barker AF, et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe α-1 antitrypsin deficiency. Respir. Res. 13, 16 (2012).
81. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 55(8), 635-642 (2000).
82. Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA. Exploring the optimum approach to the use of CT densitometry in a randomised placebocontrolled study of augmentation therapy in α 1-antitrypsin deficiency. Respir. Res. 10, 75 (2009).
83. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 62(8), 657-660 (2007).
84. Vestbo J, Anderson W, Coxson HO, et al.; ECLIPSE investigators. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur. Respir. J. 31(4), 869-873 (2008).
85. Lindberg CA, Engström G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur. Respir. J. 39(4), 839-845 (2012).
86. Fregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in α-1-antitrypsin deficiencyrelated COPD. COPD 8(5), 329-333 (2011).
87. Huang JT, Chaudhuri R, Albarbarawi O, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 67(6), 502-508 (2012).
88. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product Aa-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 66(8), 686-691 (2011).
89. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in a1-antitrypsin deficiency. Respir. Res. 12, 35 (2011).
90. Agustí A, Edwards LD, Rennard SI, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7(5), e37483 (2012).
91. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. 3(6), 675-677 (1997).
92. Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur. Respir. J. 40(2), 306-312 (2012).
93. Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 9(2), 111-120 (2012).
94. Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur. Respir. J. 40(4), 969-976 (2012).
95. Zeiher BG, Artigas A, Vincent JL, et al.; STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit. Care Med. 32(8), 1695-1702 (2004).
96. Dauriat G, Mal H, Jebrak G, et al. Functional results of unilateral lung volume reduction surgery in α1-antitrypsin deficient patients. Int. J. Chron. Obstruct. Pulmon. Dis. 1(2), 201-206 (2006).
97. Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT; National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and α-1 antitrypsin deficiency. Ann. Thorac. Surg. 83(1), 241-251 (2007).
98. Tutic M, Bloch KE, Lardinois D, Brack T, Russi EW, Weder W. Long-term results after lung volume reduction surgery in patients with α1-antitrypsin deficiency. J. Thorac. Cardiovasc. Surg. 128(3), 408-413 (2004).
99. Tuohy MM, Remund KF, Hilfiker R, Murphy DT, Murray JG, Egan JJ. Endobronchial valve deployment in severe a-1 antitrypsin deficiency emphysema: a case series. Clin. Respir. J. 7(1), 45-52 (2013).
100. Sciurba FC, Ernst A, Herth FJ, et al.; VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N. Engl. J. Med. 363(13), 1233-1244 (2010).
101. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for α 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316(17), 1055-1062 (1987).
102. Seersholm N, Wencker M, Banik N, et al. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) α1-AT study group. Eur. Respir. J. 10(10), 2260-2263 (1997).
103. Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with α(1)-protease inhibitor deficiency before and during therapy with IV α(1)-protease inhibitor. Chest 119(3), 737-744 (2001).
104. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for α1 antitrypsin deficiency: a meta-analysis. COPD 6(3), 177-184 (2009).
105. Clark KD, Wardrobe-Wong N, Elliott JJ, Gill PT, Tait NP, Snashall PD. Patterns of lung disease in a 'normal' smoking population: are emphysema and airflow obstruction found together? Chest 120(3), 743-747 (2001).
106. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of a-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir. Res. 11, 136 (2010).
107. Tonelli AR, Brantly ML. Augmentation therapy in α-1 antitrypsin deficiency: advances and controversies. Ther. Adv. Respir. Dis. 4(5), 289-312 (2010).
108. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α(1)-antitrypsin deficiency (PiZ). Am. J. Respir. Crit. Care Med. 160(6), 1968-1975 (1999).
109. Wencker M, Denker J, Konietzko N. Serial measurements of FEV1 over 12 years in a patient with α-1-protease inhibitor deficiency: influence of augmentation therapy and infections. Respiration. 61(4), 195-198 (1994).
110. Hubbard RC, Crystal RG. Strategies for aerosol therapy of α 1-antitrypsin deficiency by the aerosol route. Lung 168(Suppl.), 565-578 (1990).
111. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophilelastase defenses of the lower respiratory tract in α 1-antitrypsin deficiency directly augmented with an aerosol of α 1-antitrypsin. Ann. Intern. Med. 111(3), 206-212 (1989).
112. Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur. Respir. J. 22(2), 263-267 (2003).
113. Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I] α1-protease inhibitor: toward a new therapeutic concept of α1-protease inhibitor deficiency? J. Nucl. Med. 42(5), 744-751 (2001).
114. Gorin AB, Stewart PA. Differential permeability of endothelial and epithelial barriers to albumin flux. J. Appl. Physiol. 47(6), 1315-1324 (1979).
115. Karnaukhova E, Ophir Y, Golding B. Recombinant human α-1 proteinase inhibitor: towards therapeutic use. Amino Acids 30(4), 317-332 (2006).
116. Archibald AL, McClenaghan M, Hornsey V, Simons JP, Clark AJ. High-level expression of biologically active human α 1-antitrypsin in the milk of transgenic mice. Proc. Natl Acad. Sci. USA 87(13), 5178-5182 (1990).
117. Massoud M, Bischoff R, Dalemans W, et al. Expression of active recombinant human α 1-antitrypsin in transgenic rabbits. J. Biotechnol. 18(3), 193-203 (1991).
118. Tsymbalenko NV, Golinskii GF, Gaitskhoki VS. [Expression of the human α-1-antitrypsin gene in transgenic rats]. Biull. Eksp. Biol. Med. 120(7), 81-83 (1995).
119. Wright G, Carver A, Cottom D, et al. High level expression of active human α-1-antitrypsin in the milk of transgenic sheep. Biotechnology (NY) 9(9), 830-834 (1991).
120. Ziomek CA. Commercialization of proteins produced in the mammary gland. Theriogenology 49(1), 139-144 (1998).
121. Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-Antitrypsin Study Group. Antibody response to aerosolized transgenic human α1-antitrypsin. N. Engl. J. Med. 352(19), 2030-2031 (2005).
122. Casolaro MA, Fells G, Wewers M, et al. Augmentation of lung antineutrophil elastase capacity with recombinant human α-1-antitrypsin. J. Appl. Physiol. 63(5), 2015-2023 (1987).
123. Yu SD, Gan JC. Effects of progressive desialylation on the survival of human plasma α1-anti-trypsin in rat circulation. Int. J. Biochem. 9(2), 107-115 (1978).
124. Ross D, Brown T, Harper R, et al. Production and characterization of a novel human recombinant α-1-antitrypsin in PER.C6 cells. J. Biotechnol. doi:10.1016/j. jbiotec.2012.09.018 (2012) (Epub ahead of print).
125. Chang YP, Mahadeva R, Chang WS, Shukla A, Dafforn TR, Chu YH. Identification of a 4-mer peptide inhibitor that effectively blocks the polymerization of pathogenic Z α1-antitrypsin. Am. J. Respir. Cell Mol. Biol. 35(5), 540-548 (2006).
126. Chang YP, Mahadeva R, Chang WS, Lin SC, Chu YH. Small-molecule peptides inhibit Z α1-antitrypsin polymerization. J. Cell. Mol. Med. 13(8B), 2304-2316 (2009).
127. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z α(1)-antitrypsin-related cirrhosis. J. Biol. Chem. 277(9), 6771-6774 (2002).
128. Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R. Inhibiting polymerization: new therapeutic strategies for Z α1-antitrypsin-related emphysema. Am. J. Respir. Cell Mol. Biol. 31(2), 133-139 (2004).
129. Zhou A, Stein PE, Huntington JA, Sivasothy P, Lomas DA, Carrell RW. How small peptides block and reverse serpin polymerisation. J. Mol. Biol. 342, 931-941 (2004).
130. Elliott PR, Pei XY, Dafforn TR, Lomas DA. Topography of a 2.0 A structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9(7), 1274-1281 (2000).
131. Parfrey H, Mahadeva R, Ravenhill NA, et al. Targeting a surface cavity of α 1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278(35), 33060-33066 (2003).
132. Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z α1-antitrypsin and increase the clearance of intracellular aggregates. J. Med. Chem. 50(22), 5357-5363 (2007).
133. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant α 1-antitrypsin (α 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α 1-AT deficiency. Proc. Natl Acad. Sci. USA 97(4), 1796-1801 (2000).
134. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum α-1-antitrypsin in patients with α-1-antitrypsin deficiency: a preliminary study. J. Pediatr. Gastroenterol. Nutr. 39(1), 34-37 (2004).
135. Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal α1-antitrypsin gene in α1-antitrypsin-deficient subjects: comparison with protein therapy. Hum. Gene Ther. 11(7), 1023-1032 (2000).
136. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 αl-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17(12), 1177-1186 (2006).
137. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA 106(38), 16363-16368 (2009).
138. Chulay JD, Ye GJ, Thomas DL, et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human α-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum. Gene Ther. 22(2), 155-165 (2011).
139. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing a1-antitrypsin: interim results. Hum. Gene Ther. 22(10), 1239-1247 (2011).
140. Ozaki I, Zern MA, Liu S, Wei DL, Pomerantz RJ, Duan L. Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells. J. Hepatol. 31(1), 53-60 (1999).
141. Zern MA, Ozaki I, Duan L, Pomerantz R, Liu SL, Strayer DS. A novel SV40-based vector successfully transduces and expresses an α 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther. 6(1), 114-120 (1999).
142. Duan YY, Wu J, Zhu JL, et al. Gene therapy for human α1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology 127(4), 1222-1232 (2004).
143. Cruz PE, Mueller C, Cossette TL, et al. In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab. Invest. 87(9), 893-902 (2007).
144. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441(7092), 537-541 (2006).
145. Mueller C, Tang Q, Gruntman A, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol. Ther. 20(3), 590-600 (2012).
146. McNab GL, Ahmad A, Mistry D, Stockley RA. Modification of gene expression and increase in α1-antitrypsin (α1-AT) secretion after homologous recombination in α1-AT-deficient monocytes. Hum. Gene Ther. 18(11), 1171-1177 (2007).
147. Wilson AA, Kwok LW, Hovav AH, et al. Sustained expression of α1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am. J. Respir. Cell Mol. Biol. 39(2), 133-141 (2008).
148. Ghaedi M, Lotfi AS, Soleimani M. Establishment of lentiviral-vector- mediated model of human α-1 antitrypsin delivery into hepatocyte-like cells differentiated from mesenchymal stem cells. Tissue Cell 42(3), 181-189 (2010).
149. Li H, Lu Y, Witek RP, et al. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of α1-antitrypsin. Mol. Ther. 18(8), 1553-1558 (2010).
150. Li H, Zhang B, Lu Y, Jorgensen M, Petersen B, Song S. Adipose tissue-derived mesenchymal stem cell-based liver gene delivery. J. Hepatol. 54(5), 930-938 (2011).
151. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
152. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of a1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478(7369), 391-394 (2011).
153. Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 74(5), 481-492 (2007).
154. Entrez SNP. www.ncbi.nlm.nih.gov/projects/SNP (Accessed 7 November 2012)
155. Zemaira® in subjects with emphysema due to α1-proteinase inhibitor (API) deficiency. http://clinicaltrials.gov/ct2/show/NCT00261833 (Accessed 12 November 2012)
156. International study evaluating the safety and efficacy of inhaled, human, α-1 antitrypsin (AAT) in α-1 antitrypsin deficient patients with emphysema. http://clinicaltrials.gov/show/NCT01217671 (Accessed 12 November 2012)